| Literature DB >> 7329211 |
M O'Brien, S T Patel, A Mukhopadhyay, H A Newman, D R Feller, S S Kokrady, D T Witiak, R R Lanese, J C Rice.
Abstract
The hypolipidemic properties of ethyl 6-chlorochroman-2-carboxylate (II), ethyl 6-phenylchroman-2-carboxylate (III) and ethyl 6-cyclohexylchroman-2-carboxylate (IV) were compared to clofibrate (I) in fasted normolipidemic rats. The chroman analog II, like its parent compound, clofibrate, reduced serum and alpha-lipoprotein cholesterol concentrations. Although analog III had no effect on serum cholesterol, it caused a slight elevation of alpha-lipoprotein cholesterol concentration. Serum free cholesterol was increased and LCAT activity was reduced in clofibrate-treated rats. The hypolipidemic agents had no consistent effect on liver lipid concentrations and liver microsomal HMG-CoA reductase activity. In addition, we have shown that drug efficacies varied directly with seasonal variations in serum lipid concentrations.Entities:
Mesh：
Substances：
Year: 1981 PMID： 7329211 DOI： 10.1007/bf02534996
Source DB: PubMed Journal: Lipids ISSN： 0024-4201 Impact factor: 1.880